We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

225 hedge funds and large institutions have $3.27B invested in Neurocrine Biosciences in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 97 increasing their positions, 75 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

97.13% more ownership

Funds ownership: 0% → 97.13% (+97%)

29% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 75

6% less call options, than puts

Call options by funds: $23.6M | Put options by funds: $25.1M

8% less funds holding

Funds holding: 244 → 225 (-19)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

24% less capital invested

Capital invested by funds: $4.32B → $3.27B (-$1.05B)

37% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 41

Holders
225
Holders Change
-19
Holders Change %
-7.79%
% of All Funds
5.63%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
26
Increased
97
Reduced
75
Closed
41
Calls
$23.6M
Puts
$25.1M
Net Calls
-$1.48M
Net Calls Change
-$32.7M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.6M
2
HM
HealthCor Management
New York
+$44.8M
3
PA
Perceptive Advisors
New York
+$38M
4
Franklin Resources
Franklin Resources
California
+$18M
5
GPP
Great Point Partners
Connecticut
+$16.1M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$153M
2
EAM
Eagle Asset Management
Florida
-$46.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$35.2M
4
American Century Companies
American Century Companies
Missouri
-$25.8M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
126
Profund Advisors
Maryland
$1.48M -$275K -6,069 -14%
VOYA Investment Management
127
VOYA Investment Management
Georgia
$1.43M -$7.41M -163,648 -82%
ACI
128
Alpha Cubed Investments
California
$1.39M – – –
WMSA
129
Weiss Multi-Strategy Advisers
New York
$1.39M +$226K +5,000 +16%
BlackRock
130
BlackRock
New York
$1.36M -$1.89M -41,659 -54%
CAM
131
ClariVest Asset Management
California
$1.14M -$1.31K -29 -0.1%
Capital Fund Management (CFM)
132
Capital Fund Management (CFM)
France
$1.11M +$713K +15,760 +122%
PI
133
Putnam Investments
Massachusetts
$1.06M +$101K +2,222 +9%
VKH
134
Virtu KCG Holdings
New York
$1.05M +$336K +7,427 +38%
NIT
135
NumerixS Investment Technologies
British Columbia, Canada
$1.05M +$887K +19,600 +258%
Russell Investments Group
136
Russell Investments Group
United Kingdom
$1.02M +$1.22M +27,049 New
BC
137
Birchview Capital
Vermont
$975K – – –
SGH
138
Sivik Global Healthcare
Connecticut
$968K +$426K +9,400 +60%
FRM
139
Fox Run Management
Connecticut
$960K +$928K +20,500 +477%
TAM
140
Tocqueville Asset Management
New York
$953K -$412K -9,100 -27%
MAP
141
Moody Aldrich Partners
Massachusetts
$944K -$450K -9,945 -29%
AG
142
Aperio Group
California
$929K +$235K +5,200 +28%
TC
143
TFS Capital
Pennsylvania
$909K +$1.06M +23,493 New
JMPWA
144
JP Morgan Private Wealth Advisors
California
$906K – – –
AIM
145
Assured Investment Management
New York
$852K +$951K +21,017 +2,091%
Schroder Investment Management Group
146
Schroder Investment Management Group
United Kingdom
$780K -$319K -7,046 -26%
Two Sigma Advisers
147
Two Sigma Advisers
New York
$716K +$513K +11,327 +158%
Wolverine Trading
148
Wolverine Trading
Illinois
$673K +$787K +17,389 New
Victory Capital Management
149
Victory Capital Management
Texas
$660K +$1.63K +36 +0.2%
PCM
150
Prelude Capital Management
New York
$651K -$523K -11,560 -41%
4 5
6
7 8

NBIX Hedge Fund Activity: Q4 2016 in Review

225 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2016, worth a combined $3.27B — down 24% from $4.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of NBIX and 26 opened new positions — a net loss of 15 holders — while 75 trimmed existing stakes and 97 added.

The largest buyer was Millennium Management, adding an estimated $55.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $153M.

  • 225 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2016, down from 244 in Q3 2016.
  • Funds reported $3.27B of Neurocrine Biosciences stock for Q4 2016, down 24% quarter-over-quarter.
  • 26 funds opened new Neurocrine Biosciences positions in Q4 2016 and 41 closed out, a net change of -15 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2016 was Millennium Management, an estimated $55.6M added.
  • The largest Neurocrine Biosciences seller in Q4 2016 was T. Rowe Price Associates, an estimated $153M sold.

Based on aggregated 13F filings for Q4 2016.